Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Upstream Bio, Inc.NASDAQ: UPB
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $8.08M rose 19.2% year over year, behind the +38.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 21.3% from the prior quarter. Over 3 fiscal years it compounded at +59.9% a year.
Context
- Selling, general & admin amounted to 925.3% of revenue in FY2025, up 200.9 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $17.07M (-35.3%) for the fiscal year ending Dec 2026, a slowdown from the +53.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8.08M+21.3% QoQ
- Last fiscal yearDec 2025
- $26.41M+53.8% YoY
- LTMMar 2026
- $27.71M+38.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 26.41M USD
- Year-over-year change
- +53.8%
- 3-year CAGR
- +59.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.41M | +53.8% |
| FY2024 | 2024-12-31 | 17.17M | +60.5% |
| FY2023 | 2023-12-31 | 10.7M | +65.5% |
| FY2022 | 2022-12-31 | 6.46M | — |
Selling, General & Admin vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +38.6% is the 2nd highest of 10, against a peer median of +23.9%.
- Selling, general & admin amounts to 834.2% of revenue for UPB, versus a peer median of 95.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $176.24M USD | +26.9% | +75.5% | 81.2% | |
| LTM Mar 2026 | $157.94M USD | +14.5% | +9.9% | 239.0% | |
| LTM Mar 2026 | $127.98M USD | -57.1% | -32.5% | 21.5% | |
| LTM Mar 2026 | $79.08M USD | +23.9% | +14.3% | 110.1% | |
| LTM Sep 2026 | $74.79M USD | +15.8% | -20.9% | — | |
| LTM Sep 2026 | €61.14M EUR | +31.2% | +15.6% | — | |
| LTM Sep 2026 | $60.45M USD | +31.0% | +18.9% | 66.8% | |
| LTM Mar 2026 | $57.81M USD | +55.3% | +58.0% | — | |
| LTM Jun 2026 | $51.18M USD | -29.7% | -6.5% | 494.5% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $27.71M USD | +38.6% | +59.9% | 834.2% |
| Peer median (excluding UPB) | — | +23.9% | +14.3% | 95.6% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.21M | 2.38M | 2.37M | 2.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 1.21M | 2.38M | 2.37M | 2.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 18.66M | 31.8M | 62.97M | 136.81M |
| Selling, General & Admin | 6.46M | 10.7M | 17.17M | 26.41M |
| Operating Expenses | 25.12M | 42.49M | 80.13M | 163.22M |
| Depreciation & Amortization | 7K | 60K | 89K | 188K |
| EBITDA | (23.86M) | (20.48M) | (62.72M) | (143.26M) |
| EBITDA Margin | -1968.7% | -860.4% | -2646.3% | -5019.4% |
| Operating Income | (23.91M) | (40.11M) | (77.76M) | (160.36M) |
| Operating Margin | -1972.7% | -1685.5% | -3281.2% | -5618.8% |
| Interest Income | 205K | 4.17M | 12.12M | 16.93M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 41K | 19.58M | 14.96M | 16.92M |
| Income Before Tax | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Pre-Tax Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Net Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| EPS (Basic) | (0.66) | (1.05) | (1.49) | (2.66) |
| EPS (Diluted) | (0.66) | (1.05) | (1.49) | (2.66) |
| Weighted Avg Shares | 36.32M | 36.32M | 51.34M | 53.85M |
| Weighted Avg Shares (Diluted) | 36.32M | 36.32M | 51.34M | 53.85M |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.